MLAB · Mesa Laboratories Inc /Co/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.13M | $60.74M | $59.54M | $50.65M | $53.47M | $53.16M | $50.45M | $54.29M | $58.75M | $34.92M |
| Cost of Revenue | $23.33M | $23.41M | $22.60M | $19.46M | $20.07M | $21.06M | $19.11M | $21.52M | $22.36M | $12.71M |
| Gross Profit | $41.80M | $37.33M | $36.94M | $31.18M | $33.40M | $32.11M | $31.34M | $32.77M | $36.39M | $22.21M |
| R&D | $5.03M | $5.05M | $4.98M | $4.81M | $4.29M | $4.99M | $5.70M | $4.80M | $4.99M | $2.81M |
| SG&A | $18.47M | $17.46M | $17.96M | $18.06M | $19.44M | $17.53M | $20.21M | $16.13M | $18.20M | $11.42M |
| Total Operating Expenses | $33.82M | $32.61M | $33.88M | $31.85M | $33.47M | $32.17M | $35.94M | $29.36M | $32.39M | $19.09M |
| D&A | $1.27M | $1.31M | $1.40M | $8.13M | - | - | $8.13M | - | - | $4.57M |
| Operating Income | $7.97M | $4.72M | $3.06M | ($664.0K) | ($67.0K) | ($60.0K) | ($4.59M) | $3.40M | $4.00M | $3.12M |
| Interest Expense | $3.04M | $2.86M | $2.20M | $1.05M | $1.86M | $905.0K | $1.01M | $1.16M | $1.21M | $874.0K |
| Income Tax | $966.0K | ($477.0K) | $2.27M | ($388.0K) | ($170.0K) | ($95.0K) | ($3.97M) | $1.47M | $2.08M | ($577.0K) |
| Net Income | $3.63M | $2.48M | $4.74M | ($549.0K) | $2.12M | ($1.23M) | ($1.44M) | $451.0K | $1.31M | $2.00M |
| EPS - Basic | $0.66 | $0.45 | $0.87 | ($0.10) | $0.39 | ($0.23) | ($0.27) | $0.08 | $0.25 | $0.39 |
| EPS - Diluted | $0.65 | $0.45 | $0.85 | ($0.10) | $0.39 | ($0.23) | ($0.27) | $0.08 | $0.24 | $0.38 |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.98M | $20.42M | $21.28M | $28.21M | $28.22M | $35.62M | $32.91M | $26.10M | $32.38M | $49.35M |
| Accounts Receivable | $40.23M | $40.09M | $39.07M | $39.05M | $36.02M | $36.34M | $42.55M | $42.40M | $41.81M | $41.22M |
| Inventory | $26.56M | $27.74M | $28.11M | $32.67M | $35.97M | $32.88M | $34.64M | $33.74M | $28.04M | $24.61M |
| Accounts Payable | $5.25M | $5.09M | $6.27M | $6.04M | $4.55M | $4.81M | $6.13M | $6.29M | $7.74M | $7.90M |
| Current Assets | $105.63M | $97.43M | $98.26M | $109.35M | $118.36M | $117.66M | $118.97M | $114.19M | $116.26M | $124.32M |
| Total Assets | $434.85M | $430.35M | $435.74M | $446.80M | $741.77M | $637.19M | $661.83M | $662.98M | $656.23M | $707.37M |
| Current Liabilities | $54.40M | $48.30M | $149.49M | $44.31M | $44.18M | $39.82M | $43.36M | $41.62M | $41.51M | $48.05M |
| Long-term Debt | $68.44M | $69.38M | $70.31M | - | - | - | - | - | - | - |
| Total Liabilities | $248.16M | $251.88M | $263.25M | $301.40M | $338.81M | $249.43M | $268.35M | $275.78M | $282.00M | $313.57M |
| Stockholders' Equity | $186.69M | $178.47M | $172.50M | $145.39M | $402.96M | $387.76M | $393.48M | $387.20M | $374.24M | $393.80M |
| Retained Earnings | ($180.73M) | ($183.47M) | ($185.07M) | ($183.49M) | $71.95M | $70.70M | $74.20M | $74.44M | $74.85M | $76.67M |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $1.89M | $9.94M | - | - | ($2.81M) | - | - | $9.59M |
| Investing Cash Flow | - | - | ($1.01M) | ($270.0K) | - | - | ($225.0K) | - | - | ($653.0K) |
| Financing Cash Flow | - | - | ($8.43M) | ($9.52M) | - | - | ($1.41M) | - | - | $265.0K |
| CapEx | - | - | $1.01M | $270.0K | - | - | $225.0K | - | - | $653.0K |
| Free Cash Flow | - | - | $884.0K | $9.67M | - | - | ($3.04M) | - | - | $8.94M |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 64.2% | 61.5% | 62.0% | 61.6% | 62.5% | 60.4% | 62.1% | 60.4% | 61.9% | 63.6% |
| Operating margin | 12.2% | 7.8% | 5.1% | -1.3% | -0.1% | -0.1% | -9.1% | 6.3% | 6.8% | 8.9% |
| EBITDA margin | 14.2% | 9.9% | 7.5% | 14.7% | - | - | 7.0% | - | - | 22.0% |
| Net margin | 5.6% | 4.1% | 8.0% | -1.1% | 4.0% | -2.3% | -2.9% | 0.8% | 2.2% | 5.7% |
| Free cash flow margin | - | - | 1.5% | 19.1% | - | - | -6.0% | - | - | 25.6% |
| FCF / Net income | - | - | 0.19 | -17.61 | - | - | 2.11 | - | - | 4.48 |
| R&D / Revenue | 7.7% | 8.3% | 8.4% | 9.5% | 8.0% | 9.4% | 11.3% | 8.8% | 8.5% | 8.0% |
| SG&A / Revenue | 28.4% | 28.8% | 30.2% | 35.7% | 36.4% | 33.0% | 40.1% | 29.7% | 31.0% | 32.7% |
| Effective tax rate | 21.0% | -23.9% | 32.4% | - | -8.7% | - | - | 76.5% | 61.4% | -40.7% |
| Return on assets | 0.8% | 0.6% | 1.1% | -0.1% | 0.3% | -0.2% | -0.2% | 0.1% | 0.2% | 0.3% |
| Return on equity | 1.9% | 1.4% | 2.7% | -0.4% | 0.5% | -0.3% | -0.4% | 0.1% | 0.3% | 0.5% |
| Return on invested capital | 2.5% | 1.9% | 0.9% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.94 | 2.02 | 0.66 | 2.47 | 2.68 | 2.96 | 2.74 | 2.74 | 2.80 | 2.59 |
| Quick ratio | 1.45 | 1.44 | 0.47 | 1.73 | 1.86 | 2.13 | 1.94 | 1.93 | 2.13 | 2.07 |
| Cash ratio | 0.53 | 0.42 | 0.14 | 0.64 | 0.64 | 0.89 | 0.76 | 0.63 | 0.78 | 1.03 |
| Leverage | ||||||||||
| Debt / Equity | 0.37 | 0.39 | 0.41 | - | - | - | - | - | - | - |
| Debt / Assets | 0.16 | 0.16 | 0.16 | - | - | - | - | - | - | - |
| Debt / EBITDA | 7.40 | 11.49 | 15.74 | - | - | - | - | - | - | - |
| Interest coverage | 2.6x | 1.7x | 1.4x | -0.6x | -0.0x | -0.1x | -4.5x | 2.9x | 3.3x | 3.6x |
| Equity multiplier | 2.33 | 2.41 | 2.53 | 3.07 | 1.84 | 1.64 | 1.68 | 1.71 | 1.75 | 1.80 |
| Liabilities / Assets | 0.57 | 0.59 | 0.60 | 0.67 | 0.46 | 0.39 | 0.41 | 0.42 | 0.43 | 0.44 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | 0.14 | 0.14 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.05 |
| Inventory turnover | 0.88 | 0.84 | 0.80 | 0.60 | 0.56 | 0.64 | 0.55 | 0.64 | 0.80 | 0.52 |
| Days sales outstanding | 225d | 241d | 239d | 281d | 246d | 249d | 308d | 285d | 260d | 431d |
| Days inventory outstanding | 416d | 433d | 454d | 613d | 654d | 570d | 662d | 572d | 458d | 707d |
| Days payable outstanding | 82d | 79d | 101d | 113d | 83d | 83d | 117d | 107d | 126d | 227d |
| Cash conversion cycle | 559d | 594d | 592d | 781d | 817d | 736d | 852d | 751d | 591d | 911d |
| Valuation | ||||||||||
| P / E | 120.8x | 148.9x | 110.8x | - | 268.6x | - | - | 2077.6x | 586.8x | 670.7x |
| P / B | 2.3x | 2.1x | 3.0x | 4.1x | 1.4x | 1.5x | 2.3x | 2.3x | 2.0x | 3.4x |
| P / S | 6.7x | 6.1x | 8.8x | 11.6x | 10.6x | 10.6x | 18.3x | 16.4x | 12.9x | 38.7x |
| EV / EBITDA | 51.5x | 69.5x | 128.1x | 75.1x | - | - | 251.0x | - | - | 169.2x |
| Growth | ||||||||||
| Revenue growth (YoY) | 21.8% | 14.2% | 17.6% | 0.4% | -1.5% | -9.5% | 44.5% | -0.7% | 63.9% | - |
| Revenue CAGR (3y) | 6.0% | 19.2% | 19.5% | - | - | - | 19.0% | 16.7% | 22.6% | - |
| Revenue CAGR (5y) | 13.8% | 13.8% | 14.7% | - | - | - | 17.3% | 18.1% | 20.7% | 10.6% |
| Gross profit growth (YoY) | 25.1% | 16.3% | 18.5% | -0.5% | 1.9% | -11.8% | 41.1% | 14.5% | 57.2% | - |
| Operating income growth (YoY) | - | - | - | 85.5% | - | - | - | - | -4.9% | - |
| Net income growth (YoY) | 71.6% | - | - | 61.8% | 369.2% | - | - | - | -64.9% | - |
| EPS growth (YoY) | 66.7% | - | - | 63.0% | 387.5% | - | - | - | -65.7% | - |
| EPS CAGR (3y) | - | -13.7% | 30.8% | - | - | - | - | - | -22.2% | -29.0% |
| EPS CAGR (5y) | - | -2.5% | 31.0% | - | 13.2% | - | - | - | -16.7% | -5.7% |
| FCF growth (YoY) | - | - | -90.9% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | -13.7% | - | - | - | - | - | - | - |
| Book value growth (YoY) | -53.7% | -54.0% | 18.6% | -63.0% | 4.1% | 3.6% | -0.1% | -2.3% | -6.3% | -3.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-31.
Business segments
$249.13M totalSterilization And Disinfection Control$101.57M · 40.8%
Calibration Solutions$53.55M · 21.5%
Biopharmaceutical Development$48.63M · 19.5%
Clinical Genomics$45.39M · 18.2%
Product / service
$340.16M totalProduct$203.39M · 59.8%
Consumables$90.52M · 26.6%
Service$45.74M · 13.4%
Hardware And Software$505.0K · 0.1%
Geographic
$249.13M totalUS$116.89M · 46.9%
Other$111.79M · 44.9%
CN$20.45M · 8.2%
Peer comparison
Same SIC group: Industrial Instruments For Measurement, Display, and Control
Comparing MESA LABORATORIES INC /CO/ against the 5 most active filers in the same SIC group.
Dividends
$0.64/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.1600 |
| Feb 27, 2026 | $0.1600 |
| Nov 28, 2025 | $0.1600 |
| Aug 29, 2025 | $0.1600 |
| May 30, 2025 | $0.1600 |
| Feb 28, 2025 | $0.1600 |
| Nov 29, 2024 | $0.1600 |
| Aug 30, 2024 | $0.1600 |
| May 31, 2024 | $0.1600 |
| Feb 28, 2024 | $0.1600 |
| Nov 29, 2023 | $0.1600 |
| Aug 30, 2023 | $0.1600 |
| May 30, 2023 | $0.1600 |
| Feb 27, 2023 | $0.1600 |
| Nov 29, 2022 | $0.1600 |
| Aug 30, 2022 | $0.1600 |
| May 27, 2022 | $0.1600 |
| Feb 25, 2022 | $0.1600 |
| Nov 29, 2021 | $0.1600 |
| Aug 30, 2021 | $0.1600 |
| May 27, 2021 | $0.1600 |
| Feb 25, 2021 | $0.1600 |
| Nov 27, 2020 | $0.1600 |
| Aug 28, 2020 | $0.1600 |